Literature DB >> 26264497

Tumor-associated macrophages in cancers.

W Hu1,2,3, X Li1,2,3, C Zhang1, Y Yang1, J Jiang4,5, C Wu6,7,8.   

Abstract

Tumor-associated macrophages (TAMs) are major component of leukocytic infiltrate of tumors and play important roles in progression and regression of tumors. Tumor microenvironment determines the mutual conversion between M1 and M2 macrophages. In many kinds of tumors, M2 type macrophages are of the majority in TAMs and promote tumor progression and metastasis. The dynamic balance and interaction between TAMs and tumor cells have important effects on the occurrence and development of tumor. TAMs in malignant tumors are useful for clinical diagnosis and may provide a novel target for cancer treatment.

Entities:  

Keywords:  Cancer; Tumor-associated macrophages

Mesh:

Year:  2015        PMID: 26264497     DOI: 10.1007/s12094-015-1373-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  78 in total

Review 1.  Macrophage plasticity and polarization: in vivo veritas.

Authors:  Antonio Sica; Alberto Mantovani
Journal:  J Clin Invest       Date:  2012-03-01       Impact factor: 14.808

Review 2.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

3.  Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer.

Authors:  Tomas J Welsh; Ruth H Green; Donna Richardson; David A Waller; Kenneth J O'Byrne; Peter Bradding
Journal:  J Clin Oncol       Date:  2005-10-11       Impact factor: 44.544

4.  Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages.

Authors:  P Allavena; M Chieppa; G Bianchi; G Solinas; M Fabbri; G Laskarin; A Mantovani
Journal:  Clin Dev Immunol       Date:  2011-02-09

5.  Cancers with Higher Density of Tumor-Associated Macrophages Were Associated with Poor Survival Rates.

Authors:  Kyong Yeun Jung; Sun Wook Cho; Young A Kim; Daein Kim; Byung-Chul Oh; Do Joon Park; Young Joo Park
Journal:  J Pathol Transl Med       Date:  2015-07-15

6.  Transcriptomic analysis of human polarized macrophages: more than one role of alternative activation?

Authors:  Eleonora Derlindati; Alessandra Dei Cas; Barbara Montanini; Valentina Spigoni; Valentina Curella; Raffaella Aldigeri; Diego Ardigò; Ivana Zavaroni; Riccardo C Bonadonna
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

7.  MIF, secreted by human hepatic sinusoidal endothelial cells, promotes chemotaxis and outgrowth of colorectal cancer in liver prometastasis.

Authors:  Chun-Ting Hu; Li-Li Guo; Na Feng; Lei Zhang; Na Zhou; Li-Li Ma; Lan Shen; Gui-Hui Tong; Qian-Wen Yan; Shi-Jie Zhu; Xiu-Wu Bian; Mao D Lai; Yong-Jian Deng; Yan-Qing Ding
Journal:  Oncotarget       Date:  2015-09-08

8.  Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.

Authors:  Thorsten Hagemann; Julia Wilson; Frances Burke; Hagen Kulbe; Ninfeng Fiona Li; Annette Plüddemann; Kellie Charles; Siamon Gordon; Frances R Balkwill
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

9.  CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Authors:  Debbie C Strachan; Brian Ruffell; Yoko Oei; Mina J Bissell; Lisa M Coussens; Nancy Pryer; Dylan Daniel
Journal:  Oncoimmunology       Date:  2013-12-04       Impact factor: 8.110

10.  Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.

Authors:  Ya-Chin Hou; Ying-Jui Chao; Hui-Ling Tung; Hao-Chen Wang; Yan-Shen Shan
Journal:  Cancer       Date:  2014-05-19       Impact factor: 6.860

View more
  41 in total

1.  Modulating Macrophage Polarization through CCR2 Inhibition and Multivalent Engagement.

Authors:  Michael B Deci; Scott W Ferguson; Sydney L Scatigno; Juliane Nguyen
Journal:  Mol Pharm       Date:  2018-06-04       Impact factor: 4.939

Review 2.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.

Authors:  Padmanee Sharma; Siwen Hu-Lieskovan; Jennifer A Wargo; Antoni Ribas
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

Review 3.  Advances in engineering local drug delivery systems for cancer immunotherapy.

Authors:  Peter Abdou; Zejun Wang; Qian Chen; Amanda Chan; Daojia R Zhou; Vivienne Gunadhi; Zhen Gu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-04-07

Review 4.  Combining epigenetic and immune therapy to overcome cancer resistance.

Authors:  Stephanie Gomez; Tomasz Tabernacki; Julie Kobyra; Paige Roberts; Katherine B Chiappinelli
Journal:  Semin Cancer Biol       Date:  2019-12-23       Impact factor: 15.707

5.  SIGNET: single-cell RNA-seq-based gene regulatory network prediction using multiple-layer perceptron bagging.

Authors:  Qinhuan Luo; Yongzhen Yu; Xun Lan
Journal:  Brief Bioinform       Date:  2022-01-17       Impact factor: 11.622

Review 6.  Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.

Authors:  Zhengyi Wang; Xiaoying Wu
Journal:  Cancer Med       Date:  2020-09-02       Impact factor: 4.452

Review 7.  Acquired resistance to cancer immunotherapy.

Authors:  Arianna Draghi; Christopher Aled Chamberlain; Andrew Furness; Marco Donia
Journal:  Semin Immunopathol       Date:  2018-07-02       Impact factor: 9.623

Review 8.  Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.

Authors:  R Zou; Y Wang; S Cui; F Ye; X Zhang; M Wang
Journal:  Clin Transl Oncol       Date:  2021-05-17       Impact factor: 3.405

Review 9.  Experience with regorafenib in the treatment of hepatocellular carcinoma.

Authors:  Alessandro Granito; Antonella Forgione; Sara Marinelli; Matteo Renzulli; Luca Ielasi; Vito Sansone; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  Therap Adv Gastroenterol       Date:  2021-05-28       Impact factor: 4.409

Review 10.  Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.

Authors:  Alessandro Granito; Sara Marinelli; Antonella Forgione; Matteo Renzulli; Francesca Benevento; Fabio Piscaglia; Francesco Tovoli
Journal:  J Hepatocell Carcinoma       Date:  2021-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.